Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02901275 · ClinicalTrials.gov registry record · Phase 2
Enhancing Medication-based Analgesia in Humans
A Phase 2 study, sponsored by Johns Hopkins University.
- Completed
- Registry status
- Phase 2
- Development phase
- 29
- Enrollment target
NCT02901275: Completed Phase 2 study, sponsored by Johns Hopkins University.
NCT02901275 is a Phase 2 study that has completed, run by Johns Hopkins University. The registered enrollment target is 29 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02901275, a Phase 2 study, has completed, sponsored by Johns Hopkins University.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 29 participants
- Enrollment target
Study Summary
This is a single-group, within-subject, double-blind, double-dummy, placebo and active-controlled study evaluated whether the FDA-approved cannabinoid dronabinol (Marinol) would enhance analgesia, subjective reports, and cognitive performance when compared to the FDA-approved opioid hydromorphone (Dilaudid).
Interventions
- DRUG Within-subject test of blinded study medications
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 29 participants |
| Start Date | 2016-12 |
| Est. Completion | 2020-03-23 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02901275
The ClinicalTrials.gov registry entry for NCT02901275 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 29 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Johns Hopkins University, which has 1,448 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Within-subject test of blinded study medications is the first listed.
NCT02901275 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02901275 about?
NCT02901275 is a clinical study titled "Enhancing Medication-based Analgesia in Humans". This is a single-group, within-subject, double-blind, double-dummy, placebo and active-controlled study evaluated whether the FDA-approved cannabinoid dronabinol (Marinol) would enhance analgesia, subjective reports, and cognitive performance when compared to the FDA-approved opioid hydromorphone (D...
What is the current status of trial NCT02901275?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 29 participants. The study started on 2016-12. Estimated completion is 2020-03-23.
What interventions are being tested in trial NCT02901275?
The interventions under investigation include: Within-subject test of blinded study medications (DRUG).
Who is sponsoring clinical trial NCT02901275?
This trial is sponsored by Johns Hopkins University, which has 1,448 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.